Listen to Story Calcium 500 mg and Vitamin D3 tablets manufactured by Life Max Cancer Laboratories were among the drugs that failed quality test. The Central Drugs Standard Control Organisation (CDSCO) has published its monthly report for September, identifying 49 pharmaceutical products that did not meet the required quality standards out of a total of 3,000 sampled drugs. The CDSCO also flagged four medicines, manufactured by fake companies, as spurious.
The non-standard drugs have been recalled on a batch-wise basis as part of CDSCO's efforts to ensure public safety. According to CDSCO Chief Rajeev Singh Raghuvanshi, only about 1% of all drugs tested failed to meet quality benchmarks, indicating that the stringent monitoring measures are effectively controlling substandard drug production. Some of the flagged products included Metronidazole tablets by Hindustan Antibiotics, Domperidone tablets from Rainbow Life Sciences, and Oxytocin injections by Pushkar Pharma.
Other notable mentions were Metformin by Swiss Biotech Parentarels, Calcium 500 mg, Vitamin D3 250 IU tablets by Life Max Cancer Laboratories, and PAN 40 from Alkem Labs. Paracetamol tablets produced by Karnataka Antibiotics & Pharmaceuticals Ltd were specifically highlighted for quality issues. Additionally, the list included a Gauze Roll Non-Sterile Roller Bandage and Diclofenac Sodium tablets among others.
This monthly vigilance action by CDSCO is part of a concerted effort to reduce the presence of non-standar.